Nature Medicine, Published online: 13 February 2025; doi:10.1038/s41591-025-03581-2
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
